Massachusetts General Hospital

Inequities across all facets of health care — from clinical research to patient outcomes — are not new.

Nearly three-quarters of patients who received lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma achieved objective response, according to results of the TRANSCEND NHL 001 trial published in The Lancet.

An analysis of the VICTORIA trial showed that the benefits of vericiguat in HF with reduced ejection fraction was consistent across various background therapies for HFrEF, a speaker reported.

How much risk is too much? It depends on what is at stake.

Sacituzumab govitecan significantly improved PFS and OS compared with single-agent chemotherapy.

Global health, physical function, pain intensity, pain interference and depression are patient-reported outcome measures that should be integrated into clinical decision-making, according to a foot and ankle surgeon.

Development of immune effector cell-associated neurotoxicity syndrome did not negatively affect survival outcomes among patients treated with axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma, study results showed.

A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral density after 15 months of overlapping teriparatide and denosumab therapy, according to a speaker.

Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared with denosumab, according to a study data.

Fatima Cody Stanford, MD, MPA, MPH, FAAP, FACP, FAHA, FTOS, is an obesity medicine physician, internist and pediatrician at Massachusetts General Hospital (MGH) and Harvard Medical School. She is the director of diversity at the Nutrition Obesity Research Center at Harvard, director of MGH Neuroendocrine Anti-Racism Initiatives, and member of the MGH Mongan Institute for Health Policy and Midlife Women’s Health Center Leadership Team.